Myriad Genetics (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal second-quarter 2018, provided an update on recent business highlights, raised its fiscal year 2018 financial guidance, and issued fiscal third-quarter 2018 financial guidance. As quoted in the press release: “We exceeded our financial expectations in the …

As quoted in the press release:

“We exceeded our financial expectations in the first half of fiscal year 2018 as a result of strong hereditary cancer volume trends, solid GeneSight^® revenue growth, and significant progress on our Elevate 2020 profitability program,” said Mark C. Capone, president and CEO, Myriad Genetics. “Based upon this strong performance we are increasing our financial guidance for fiscal 2018. We remain highly encouraged that our strategy to build upon the solid foundation of our hereditary cancer business with diversified revenues from our industry-leading pipeline of new products will deliver significant future revenue and earnings growth.”

Click here to read the full press release.